The stock price of Clover Health Investments Corp (NASDAQ: CLOV) has surged by 1.09 when compared to previous closing price of 3.66, but the company has seen a 9.14% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-07 that Clover Health Investments’ AI capabilities are a major driver for its topline and bottom-line improvements in FY 2024. Clover Health’s MCR in Q4 represented a decline from Q3, unlike past years, and rivaled its Q2 MCR, a sign of the impact of its AI capabilities. While Clover expects its margins to contract in FY 2025, its increased investments this year set it up for a highly profitable future starting from FY 2026, in my opinion.
Is It Worth Investing in Clover Health Investments Corp (NASDAQ: CLOV) Right Now?
CLOV has 36-month beta value of 1.99. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CLOV is 382.76M, and currently, short sellers hold a 3.11% ratio of that float. The average trading volume of CLOV on March 18, 2025 was 6.16M shares.
CLOV’s Market Performance
CLOV’s stock has seen a 9.14% increase for the week, with a -18.50% drop in the past month and a 18.59% gain in the past quarter. The volatility ratio for the week is 7.04%, and the volatility levels for the past 30 days are at 7.62% for Clover Health Investments Corp The simple moving average for the last 20 days is -5.70% for CLOV stock, with a simple moving average of 22.53% for the last 200 days.
Analysts’ Opinion of CLOV
Many brokerage firms have already submitted their reports for CLOV stocks, with Craig Hallum repeating the rating for CLOV by listing it as a “Buy.” The predicted price for CLOV in the upcoming period, according to Craig Hallum is $6 based on the research report published on December 17, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see CLOV reach a price target of $4. The rating they have provided for CLOV stocks is “Neutral” according to the report published on October 07th, 2024.
Cowen gave a rating of “Market Perform” to CLOV, setting the target price at $3 in the report published on February 02nd of the previous year.
CLOV Trading at -9.20% from the 50-Day Moving Average
After a stumble in the market that brought CLOV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.02% of loss for the given period.
Volatility was left at 7.62%, however, over the last 30 days, the volatility rate increased by 7.04%, as shares sank -17.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.46% upper at present.
During the last 5 trading sessions, CLOV rose by +9.14%, which changed the moving average for the period of 200-days by +266.34% in comparison to the 20-day moving average, which settled at $3.92. In addition, Clover Health Investments Corp saw 17.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CLOV starting from Edwards Carladenise Armbrister, who sale 200,000 shares at the price of $3.61 back on Mar 07 ’25. After this action, Edwards Carladenise Armbrister now owns 273,227 shares of Clover Health Investments Corp, valued at $722,000 using the latest closing price.
Priest Brady Patrick, the CEO of Home Care of Clover Health Investments Corp, sale 75,000 shares at $3.68 during a trade that took place back on Mar 06 ’25, which means that Priest Brady Patrick is holding 2,418,151 shares at $276,000 based on the most recent closing price.
Stock Fundamentals for CLOV
Current profitability levels for the company are sitting at:
- -0.03 for the present operating margin
- 0.27 for the gross margin
The net margin for Clover Health Investments Corp stands at -0.03. The total capital return value is set at -0.12. Equity return is now at value -14.75, with -8.04 for asset returns.
Currently, EBITDA for the company is -44.94 million with net debt to EBITDA at 4.41. When we switch over and look at the enterprise to sales, we see a ratio of 1.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.61.
Conclusion
To put it simply, Clover Health Investments Corp (CLOV) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
